Objective To investigate the predictive value of serum fibroblast growth factor 23 (FGF23) and S100A12 for atherosclerosis cardiovascular disease (ASCVD) in elderly patients with diabetes.
Methods A total of 133 elderly patients with diabetes were selected as the study subjects and divided into diabetes group (n=59) and ASCVD group (n=74) according to whether they had ASCVD or not. Healthy subjects who underwent physical examination at the same time were selected as the control group (n=56). The expression levels of serum FGF23 and S100A12 were detected and compared. Multivariate Logistic regression analysis was used to analyze the influencing factors of ASCVD in elderly diabetic patients. The predictive value of serum FGF23 and S100A12 levels for the occurrence of ASCVD was evaluated.
Results The proportion of hypertension, fasting blood glucose and diabetes course in the ASCVD group were significantly higher or longer than those in the diabetes group (P < 0.05). The expression levels of serum FGF23 and S100A12 in the ASCVD group were significantly higher than those in the diabetes group and control group (P < 0.05). The expression levels of hypertension, serum FGF23 and S100A12 were the independent influencing factors for ASCVD in elderly patients with diabetes (P < 0.05). The area under the curve (AUC) of serum FGF23 and S100A12 to predict ASCVD in elderly diabetic patients were 0.755 and 0.874, respectively, and the AUC of serum FGF23 and S100A12 combined to predict ASCVD was 0.934, and the sensitivity and specificity were 82.43% and 89.83%, respectively. The combined prediction of serum FGF23 and S100A12 was better than the single prediction (P < 0.05).
Conclusion Serum levels of FGF23 and S100A12 are increased in elderly patients with diabetes. The combination of serum FGF23 and S100A12 has a higher value in predicting ASCVD in elderly diabetic patients compared to their lonely detection.
DownLoad: